Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

BMI1 is a therapeutic target in recurrent medulloblastoma.

Bakhshinyan D, Venugopal C, Adile AA, Garg N, Manoranjan B, Hallett R, Wang X, Mahendram S, Vora P, Vijayakumar T, Subapanditha M, Singh M, Kameda-Smith MM, Qazi M, McFarlane N, Mann A, Ajani OA, Yarascavitch B, Ramaswamy V, Farooq H, Morrissy S, Cao L, Sydorenko N, Baiazitov R, Du W, Sheedy J, Weetall M, Moon YC, Lee CS, Kwiecien JM, Delaney KH, Doble B, Cho YJ, Mitra S, Kaplan D, Taylor MD, Davis TW, Singh SK.

Oncogene. 2019 Mar;38(10):1702-1716. doi: 10.1038/s41388-018-0549-9. Epub 2018 Oct 22.

PMID:
30348991
2.

FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells.

Manoranjan B, Wang X, Hallett RM, Venugopal C, Mack SC, McFarlane N, Nolte SM, Scheinemann K, Gunnarsson T, Hassell JA, Taylor MD, Lee C, Triscott J, Foster CM, Dunham C, Hawkins C, Dunn SE, Singh SK.

Stem Cells. 2013 Jul;31(7):1266-77. doi: 10.1002/stem.1401.

3.

MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.

Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Vecchio LD, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M.

PLoS One. 2009;4(3):e4998. doi: 10.1371/journal.pone.0004998. Epub 2009 Mar 24.

4.

Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion.

Merve A, Dubuc AM, Zhang X, Remke M, Baxter PA, Li XN, Taylor MD, Marino S.

Acta Neuropathol Commun. 2014 Jan 24;2:10. doi: 10.1186/2051-5960-2-10.

5.

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV.

Cell Cycle. 2006 Aug;5(16):1886-901. Epub 2006 Aug 15.

PMID:
16963837
6.

Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma.

Badodi S, Dubuc A, Zhang X, Rosser G, Da Cunha Jaeger M, Kameda-Smith MM, Morrissy AS, Guilhamon P, Suetterlin P, Li XN, Guglielmi L, Merve A, Farooq H, Lupien M, Singh SK, Basson MA, Taylor MD, Marino S.

Cell Rep. 2017 Dec 5;21(10):2772-2784. doi: 10.1016/j.celrep.2017.11.021.

7.

OTX2 exhibits cell-context-dependent effects on cellular and molecular properties of human embryonic neural precursors and medulloblastoma cells.

Kaur R, Aiken C, Morrison LC, Rao R, Del Bigio MR, Rampalli S, Werbowetski-Ogilvie T.

Dis Model Mech. 2015 Oct 1;8(10):1295-309. doi: 10.1242/dmm.020594. Epub 2015 Aug 6.

8.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
9.

The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer.

Yoo YA, Vatapalli R, Lysy B, Mok H, Desouki MM, Abdulkadir SA.

J Natl Cancer Inst. 2019 Mar 1;111(3):311-321. doi: 10.1093/jnci/djy142.

PMID:
30312426
10.

Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.

Bassani B, Bartolini D, Pagani A, Principi E, Zollo M, Noonan DM, Albini A, Bruno A.

PLoS One. 2016 Jul 1;11(7):e0154111. doi: 10.1371/journal.pone.0154111. eCollection 2016.

11.

Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes.

Morrison LC, McClelland R, Aiken C, Bridges M, Liang L, Wang X, Di Curzio D, Del Bigio MR, Taylor MD, Werbowetski-Ogilvie TE.

Neoplasia. 2013 Apr;15(4):384-98.

12.

Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.

Okolie O, Irvin DM, Bago JR, Sheets K, Satterlee A, Carey-Ewend AG, Lettry V, Dumitru R, Elton S, Ewend MG, Miller CR, Hingtgen SD.

PLoS One. 2018 Jul 10;13(7):e0198596. doi: 10.1371/journal.pone.0198596. eCollection 2018.

13.

Medulloblastoma-derived tumor stem-like cells acquired resistance to TRAIL-induced apoptosis and radiosensitivity.

Yu CC, Chiou GY, Lee YY, Chang YL, Huang PI, Cheng YW, Tai LK, Ku HH, Chiou SH, Wong TT.

Childs Nerv Syst. 2010 Jul;26(7):897-904. doi: 10.1007/s00381-010-1087-0. Epub 2010 Feb 24.

PMID:
20179950
14.

Medulloblastoma stem cells: where development and cancer cross pathways.

Manoranjan B, Venugopal C, McFarlane N, Doble BW, Dunn SE, Scheinemann K, Singh SK.

Pediatr Res. 2012 Apr;71(4 Pt 2):516-22. doi: 10.1038/pr.2011.62. Epub 2012 Feb 8. Review.

PMID:
22430388
15.

NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.

Fiaschetti G, Schroeder C, Castelletti D, Arcaro A, Westermann F, Baumgartner M, Shalaby T, Grotzer MA.

Acta Neuropathol Commun. 2014 Apr 7;2:39. doi: 10.1186/2051-5960-2-39.

16.

Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.

Rodriguez-Blanco J, Pednekar L, Penas C, Li B, Martin V, Long J, Lee E, Weiss WA, Rodriguez C, Mehrdad N, Nguyen DM, Ayad NG, Rai P, Capobianco AJ, Robbins DJ.

Oncogene. 2017 Nov 9;36(45):6306-6314. doi: 10.1038/onc.2017.232. Epub 2017 Jul 17.

17.

Silencing BMI1 eliminates tumor formation of pediatric glioma CD133+ cells not by affecting known targets but by down-regulating a novel set of core genes.

Baxter PA, Lin Q, Mao H, Kogiso M, Zhao X, Liu Z, Huang Y, Voicu H, Gurusiddappa S, Su JM, Adesina AM, Perlaky L, Dauser RC, Leung HC, Muraszko KM, Heth JA, Fan X, Lau CC, Man TK, Chintagumpala M, Li XN.

Acta Neuropathol Commun. 2014 Dec 20;2:160. doi: 10.1186/s40478-014-0160-4.

18.

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A.

J Clin Oncol. 2015 Aug 20;33(24):2646-54. doi: 10.1200/JCO.2014.60.1591. Epub 2015 Jul 13.

19.

Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.

Ahmad Z, Jasnos L, Gil V, Howell L, Hallsworth A, Petrie K, Sawado T, Chesler L.

PLoS One. 2015 Mar 18;10(3):e0119834. doi: 10.1371/journal.pone.0119834. eCollection 2015.

20.

Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.

Menyhárt O, Giangaspero F, Győrffy B.

J Hematol Oncol. 2019 Mar 15;12(1):29. doi: 10.1186/s13045-019-0712-y. Review.

Supplemental Content

Support Center